Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
(firmenpresse) - HALIFAX, NOVA SCOTIA -- (Marketwired) -- 04/28/16 -- Immunovaccine Inc. ("Immunovaccine" or the "company") (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that will present an update on the Company''s recent progress and future strategy at the 2016 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Tuesday, May 3, 2016 at 3:00 p.m. Eastern Time.
The presentation will be available on Immunovaccine''s website at following the presentation.
This year marks Bloom Burton & Co.''s fifth annual . It brings together Canadian, U.S. and international investors who are interested in the latest developments in the Canadian healthcare sector. Investors will have the opportunity to obtain corporate updates from presenting companies, and participate in one-on-one meetings with company management.
About Immunovaccine
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company''s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). In collaboration with commercial and academic partners, Immunovaccine is also expanding the application of DepoVax™ as an adjuvanting platform for vaccines targeted against infectious diseases. Immunovaccine''s goal in infectious diseases is to out-license its DepoVax™ platform to partners to generate earlier revenues. For more information, visit .
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.
Contacts:
MEDIA
Sam Brown Inc.
Mike Beyer
(312) 961-2502
INVESTOR RELATIONS
Immunovaccine Inc.
Kimberly Stephens
Chief Financial Officer
(902) 492-1819
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.04.2016 - 05:05 Uhr
Sprache: Deutsch
News-ID 1431190
Anzahl Zeichen: 3810
contact information:
Contact person:
Town:
HALIFAX, NOVA SCOTIA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 174 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Immunovaccine Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
